Home › Funds › Viking Global Investors › AMLX
Viking Global Investors position in AMLX
AMYLYX PHARMACEUTICALS INC · Health Care
Latest position (Q4 2023)2.96M sh
Reported value held$43.61M
Portfolio Weight0.16%
First reportedQ1 2022
Last changeHold
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2022 | 7.17M | $92.14M | New |
| Q2 2022 | 7.17M | $138.10M | Hold |
| Q3 2022 | 5.77M | $162.44M | Reduce |
| Q4 2022 | 4.63M | $171.25M | Reduce |
| Q1 2023 | 2.96M | $86.92M | Reduce |
| Q2 2023 | 2.96M | $63.90M | Hold |
| Q3 2023 | 2.96M | $54.24M | Hold |
| Q4 2023 | 2.96M | $43.61M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding AMLX
- Fidelity Management & Research (FMR) 16.73M sh · $300.43M · Q2 2026
- BlackRock Inc 8.83M sh · $158.53M · Q2 2026
- Vanguard Group 5.80M sh · $70.12M · Q4 2025
- Janus Henderson Group 4.99M sh · $69.26M · Q1 2026
- Morgan Stanley 3.13M sh · $56.23M · Q2 2026
- Franklin Resources 2.95M sh · $52.99M · Q2 2026
- Goldman Sachs Group 2.86M sh · $51.33M · Q2 2026
- Geode Capital Management 2.34M sh · $41.95M · Q2 2026
- JPMorgan Chase & Co 1.86M sh · $34.92M · Q2 2026
- Northern Trust Corp 831.74K sh · $14.94M · Q2 2026
- Bank of America Corp 821.84K sh · $14.76M · Q2 2026
- Charles Schwab Investment Management 725.03K sh · $13.02M · Q2 2026